Novavax raises 2026 revenue outlook, flags Sanofi trial talks and C. diff progress
Novavax lifted its full-year revenue framework to $235-$275 million and said Sanofi is in advanced regulatory talks over its combination COVID-flu trial timing.
SEC filing